Picture of Skinbiotherapeutics logo

SBTX Skinbiotherapeutics News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

REG - AIM - AIM Notice - 07/08/2024

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240807:nRSG4255Za&default-theme=true

RNS Number : 4255Z  AIM  07 August 2024

NOTICE

 

07/08/2024 - 08:00

 

The London Stock Exchange admits the following securities to trading on AIM:

 

 ALIEN METALS LIMITED
 545,454,545  COMMON SHARES OF NO PAR VALUE, FULLY PAID, (DI)  (BGRSF03)(VGG017351021)

 

 MOBILE STREAMS PLC
 1,210,000,000  ORDINARY SHARES OF 0.01P EACH, FULLY PAID  (B0WJ3L6)(GB00B0WJ3L68)

 

 SKINBIOTHERAPEUTICS PLC
 14,875,749  ORDINARY SHARES OF 1P EACH, FULLY PAID  (BF33H87)(GB00BF33H870)

 

AMENDMENT

 

Following a Capital Reorganisation the following security has been amended:

 

 CHALLENGER ENERGY GROUP PLC
   ORDINARY SHARES OF 0.02P EACH, FULLY PAID  (BN2RD44)(IM00BN2RD444)

 

This should appear as:

 

 CHALLENGER ENERGY GROUP PLC
   ORDINARY SHARES OF 1P EACH, FULLY PAID  (BPLZ1D8)(IM00BPLZ1D89)

 

If you have any queries or require further information, please contact Market
Operations on 020 7797 4310.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AMOBUGDIBBGDGSL

Recent news on Skinbiotherapeutics

See all news